Logistics Reimagined: The Benefits of Using a Virtual 3PL Vendor
One of the most significant advantages of a virtual 3PL is the ability to operate without the overhead costs associated with traditional 3PLs. A virtual 3PL can streamline order-to-cash operations by leveraging technology and automation solutions, potentially resulting in more competitive pricing for manufacturers. Virtual 3PLs are typically more flexible and open to process customization and less concerned with scalability compared to some traditional 3PLs. This could lessen financial burdens for small and medium-sized manufacturers with limited resources to invest in their own order-to-cash infrastructure. Whether a company manages inventory operations internally or externally, this approach can remove the risk of “going all in” with a single, traditional 3PL partner.
3PL partners are integral to many pharmaceutical supply chain solutions and distribution models. They are more than pick, pack, and ship operations providers—most offer seamless support across all storage, distribution, and backend functions while creating a strategic partnership with their manufacturer base. The newly developed virtual 3PL concept could be a more cost-effective, flexible, and efficient option for smaller biopharma clients looking to outsource their order-to-cash operations and optimize their supply chains.
Could these specialized services be the unique, white-glove, attainable solution the market is waiting for? We’ll continue to monitor this concept to see if it gains popularity and expands in the market. Stay tuned as we gain feedback from those who adopt the virtual 3PL approach.
Learn more about our distribution team and the differentiators that matter most to manufacturers, and contact us today for assistance with your strategic and tactical distribution needs.
For additional insights on this topic, you may also enjoy the following:
Revolutionizing Patient Care: The Top 5 Benefits of Investing in Innovation
Why manufacturers must embrace innovative trends to stay ahead
FDA Extends Compliance Deadline for Updated DSCSA Requirements
Understanding the revised timeline for compliance with specific updated DSCSA requirements
Are Direct-to-Patient Access Models the Future of Pharma?
Understanding the opportunity to sell directly to patients via a cash model
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|